IONS
Ionis PharmaceuticalsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IONS Profile
Ionis Pharmaceuticals, Inc.
The leader in RNA-targeted therapy and pioneering new markets and changing standards of care with its novel antisense technology
2855 Gazelle Court, Carlsbad, CA 92010
--
Ionis Pharmaceuticals, Inc. is an industry leader in the invention and development of antisense drugs. Using the new drug research and development platform, the company has developed a large number of first-class drugs. Antisense technology opens a channel between genetics and medicine. With the company's efficient and prolific drug R&D platform, the company can use antisense drugs to expand the types of drugs for itself and its partners to meet a large number of drug needs. The company's strategy is to do what the company does best -- to find unique antisense drugs and develop those drugs to become critical clinical value turning points. The company invents and conducts early research on new drugs, and then licenses the drugs to partners. The company maximizes the value of drugs by handing them over to leading pharmaceutical companies for late-stage development, such as Biogen Idec, Bristol-Myers Squibb Company, Genzyme, Sanofi, GlaxoSmithKline and Eli Lilly.
The company's flagship product, KYNAMRO, is moving towards the market for patients with familial hypercholesterolemia.
The company was founded in 1989 in California, USA.
